Abstract: The present disclosure identifies pathways, mechanisms, systems and methods to confer chemoautotrophic production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in organisms such that these organisms efficiently convert inorganic carbon to organic carbon-based products of interest using inorganic energy, such as formate, and in particular the use of organisms for the commercial production of various carbon-based products of interest.
Type:
Grant
Filed:
October 30, 2012
Date of Patent:
February 27, 2018
Assignee:
Ginkgo BioWorks, Inc.
Inventors:
Curt R. Fischer, Austin J. Che, Reshma P. Shetty, Jason R. Kelly
Abstract: The invention is directed to a process for the biological conversion of bisulphide into elemental sulphur, comprising the following steps: a) converting bisulphide as dissolved in an aqueous solution to elemental sulphur in the presence of sulphide-oxidizing bacteria and under anaerobic conditions to obtain a first liquid effluent comprising elemental sulphur and used sulphide-oxidizing bacteria; b) regenerating the used sulphide-oxidizing bacteria as obtained in step (a) and as comprised in an aqueous solution in the presence of an oxidant to obtain a second liquid effluent comprising regenerated sulphide-oxidizing bacteria; c) separating elemental sulphur from either the first and/or the second liquid effluent; d) using the regenerated sulphide-oxidizing bacteria in step (a) as the sulphide-oxidizing bacteria.
Type:
Grant
Filed:
January 30, 2015
Date of Patent:
February 27, 2018
Assignee:
PAQELL B.V.
Inventors:
Johannes Bernardus Maria Klok, Albert Joseph Hendrik Janssen, Gijsbert Jan Van Heeringen, Jan-Henk Van Dijk
Abstract: This document describes biochemical pathways for producing 2(E)-heptenedioyl-CoA methyl ester from precursors such as 2-oxo-glutarate, acetyl-CoA, or succinyl-CoA using one or more of a fatty acid O-methyltransferase, a thioesterase, a CoA-transferase, a CoA ligase, as well as recombinant hosts expressing one or more of such enzymes. 2(E)-heptenedioyl-CoA methyl ester can be enzymatically converted to pimeloyl-CoA using a trans-2-enoyl-CoA reductase, and a methylesterase. Pimeloyl-CoA can be enzymatically converted to pimelic acid, 7-aminoheptanoate, 7-hydroxyheptanoate, heptamethylenediamine, or 1,7-heptanediol.
Type:
Grant
Filed:
June 16, 2015
Date of Patent:
February 20, 2018
Assignee:
INVISTA NORTH AMERICA S.A.R.L.
Inventors:
Alex Van Eck Conradie, Adriana Leonora Botes
Abstract: The present invention relates to the purification of vitamin K-dependent blood coagulation factors, such as Factor IX (FIX). In particular, the invention provides a method for purifying Factor IX having a desired content of gamma-carboxyglutamic acid from a sample comprising a mixture of species of said Factor IX having different contents of gamma-carboxyglutamic acid, said method comprising the steps of: (a) loading said Factor IX sample onto an immunoaffinity chromatography material coupled to a binding moiety for gamma-carboxyglutamic acid; (b) eluting said Factor IX; and (c) selecting a fraction obtained from said elution wherein the polypeptides in the fraction have the desired content of gamma-carboxyglutamic acids; characterized in that the total concentration of Factor IX within said sample exceeds the binding ability of the immunoaffinity chromatography material.
Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).
Type:
Grant
Filed:
June 4, 2013
Date of Patent:
February 13, 2018
Assignee:
CONTRAFECT CORPORATION
Inventors:
Raymond Schuch, Robert C. Nowinski, Michael Wittekind, Han Lee, Brent Schneider
Abstract: A chemical having the formula (S) 2-amino-6-hydroxypimelate. (S)-2-amino-6-hydroxypimelate can be made using a method comprising culturing a cell comprising an exogenous nucleic acid sequence encoding an enzyme that catalyzes the substrate to product conversion of (S)-2-amino-6-oxopimelate to (S)-2-amino-6-hydroxypimelate and separating the (S)-2-amino-6-hydroxypimelate. The cell may be a recombinant microorganism for producing aminocaproic acid or hexamethylenediamine from (S)-2-amino-6-hydroxypimelate comprising at least one exogenous nucleic acid sequence that expresses at least one polypeptide with substrate preference for homolysine, and amino acid decarboxylase with substrate preference for alpha-aminopimelate.
Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for modulating or altering recombination inside or outside of a cell using isolated and/or purified polypeptides and/or nucleic acid sequences from Alicyclobacillus acidocaldarius.
Type:
Grant
Filed:
December 30, 2016
Date of Patent:
February 13, 2018
Assignee:
Battelle Energy Alliance, LLC
Inventors:
Brady D. Lee, Deborah T. Newby, Jeffrey A. Lacey, David N. Thompson, Vicki S. Thompson, William A. Apel, Francisco F. Roberto, David W. Reed
Abstract: The present invention provides for an isolated or recombinant polypeptide comprising an amino acid sequence having at least 70% identity with the amino acid sequence of a Halorhabdus utahensis cellulase, such as Hu-CBH1, wherein said amino acid sequence has a halophilic thermostable and/or thermophilic cellobiohydrolase (CBH) activity. In some embodiments, the polypeptide has a CBH activity that is resistant to up to about 20% of ionic liquids. The present invention also provides for compositions comprising and methods using the isolated or recombinant polypeptide.
Type:
Grant
Filed:
May 25, 2016
Date of Patent:
January 9, 2018
Assignees:
The Regents of the University of California, Sandia Corporation
Inventors:
Tao Zhang, Supratim Datta, Blake A. Simmons, Edward M. Rubin
Abstract: Methods for the fermentative production of four carbon alcohols is provided. Specifically, butanol, preferably isobutanol is produced by the fermentative growth of a recombinant bacterium expressing an isobutanol biosynthetic pathway.
Type:
Grant
Filed:
March 11, 2016
Date of Patent:
January 9, 2018
Assignee:
Butamax Advanced Biofuels LLC
Inventors:
Gail K. Donaldson, Andrew C. Eliot, Dennis Flint, Lori Ann Maggio-Hall, Vasantha Nagarajan
Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.
Abstract: Disclosed is a continuous process for separating or extracting proteins from a low grade mixture of a protein of interest, other proteins, impurities, and salts in a continuous simulated moving bed separation process. The invention provides for direct extraction of heme protein and plant protein from a crude mixture of such proteins, other proteins, impurities and salts using the chromatographic technique of simulated moving bed (SMB) continuous chromatography. The SMB process combines the steps of feed loading, adsorbent washing, product elution, adsorbent regeneration, and adsorbent equilibration. The novel strong anion exchange resin adsorbent is a quaternary amine cross-linked microcellulose wherein the microcellulose is cross-linked with epichlorohydrin and the quaternary amine is 2,3-epoxypropyltrimethyl-ammonium chloride which exhibits selective adsorption of proteins and complete regeneration.
Type:
Grant
Filed:
September 8, 2015
Date of Patent:
November 21, 2017
Assignee:
OROCHEM TECHNOLOGIES, INC.
Inventors:
Anil R. Oroskar, Babu Siddegowda Antharavally, Anantha Krishna Mallia
Abstract: The present invention relates to processes for producing fermentation products from starch-containing material, wherein a thermostable alpha-amylase and optionally a thermostable protease are present and/or added during liquefaction. The invention also relates to a composition suitable for use in a process of the invention.
Type:
Grant
Filed:
December 21, 2011
Date of Patent:
November 14, 2017
Assignee:
NOVOZYMES A/S
Inventors:
Randy Deinhammer, Suzanne Clark, Mauricio Quiros, John Matthews, Anne Glud Hjulmand, Chee Leong Soong, Tomoko Matsui, Shinobu Takagi
Abstract: The present invention provides tools and methods for producing organic acids using strains of Monascus which are tolerant to high organic acid concentrations at low pH.
Type:
Grant
Filed:
October 28, 2011
Date of Patent:
November 7, 2017
Assignee:
TOTAL RESEARCH & TECHNOLOGY FELUY
Inventors:
Alexander Ruud Weusthuis, Emil Johan Harald Wolbert, Jan Springer, John Van Der Oost, Gerrit Eggink
Abstract: A thermostable cellobiohydrolase, having a cellobiohydrolase catalytic domain including: (A) a polypeptide including the amino acid sequence represented by SEQ ID NO: 1 or 2, (B) a polypeptide including an amino acid sequence in which at least one amino acid has been deleted, substituted, or added in the amino acid sequence represented by SEQ ID NO: 1 or 2, and having hydrolysis activity against a substrate of phosphoric acid swollen Avicel at least under conditions of 75° C. and pH 5, or (C) a polypeptide including an amino acid sequence having 60% or greater sequence identity with the amino acid sequence represented by SEQ ID NO: 1 or 2, and having hydrolysis activity against a substrate of phosphoric acid swollen Avicel at least under conditions of 75° C. and pH 5.
Abstract: The present invention is directed to nucleic acid and amino acid sequences of a novel piggyBac transposase enzymes created by modifying the transposase of Trichoplusia ni. The piggyBac transposases of the present invention are functionally active or hyperactive for excision and have decreased integration activity compared to wild type Trichoplusia ni piggyBac transposase enzyme. These transposases are ideal for use in methods of transforming cells and organisms. In particular embodiments, the present invention provides methods of transient integration and expression of transgenes.
Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
Abstract: The present invention relates to variants of alpha amylase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Type:
Grant
Filed:
January 11, 2016
Date of Patent:
September 19, 2017
Assignee:
NOVOZYMES A/S
Inventors:
Tomoko Matsui, Aki Tomiki, Guillermo Coward-Kelly
Abstract: Purified Ref polypeptides with increased nuclease site-specific targeting activity, recombinant nucleic acids and cells for expression of such Ref polypeptides, and methods for using the Ref polypeptides in combination with RecA protein and variants thereof to effect targeted nuclease cleavage of a DNA duplex are disclosed.
Type:
Grant
Filed:
March 10, 2017
Date of Patent:
September 5, 2017
Assignee:
WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventors:
Michael M. Cox, Angela J. Gruber, Tayla M. Olsen
Abstract: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies.
Type:
Grant
Filed:
July 22, 2016
Date of Patent:
August 22, 2017
Assignees:
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, SA, Tecnifar—Industria Tecnica Farmaceutica, S.A.
Inventors:
Miguel Ângelo Da Costa Garcia, Carlos Jorge Sousa De São José, Clara Isabel Rodrigues Leandro, Filipa Maria Rodrigues Pardal Dias Antunes Marçal Da Silva, Ana Raquel Martins Barbosa